Jubilant and Eli Lilly extend R&D pact for 5 yrs

Jubilant Organosys Ltd through its Bangalore based subsidiary Jubilant Biosys Ltd has extended its drug discovery research collaboration with Eli Lilly & Company for another five years.

Jubilant Organosys Ltd through its Bangalore based subsidiary Jubilant Biosys Ltd has extended its drug discovery research collaboration with Eli Lilly & Company for another five years. Under the terms of the new agreement, Jubilant will receive research funding and success-based discovery and development milestones.

HT Image

Jubilant and Lilly had entered into initial discovery research collaboration in late 2005 and have so far delivered multiple discovery milestones and pre-clinical candidates, resulting in a five-year extension .

Shyam S. Bhartia, CMD, Jubilant Organosys said, “We look forward to strengthening this partnership for better outcomes in pursuit of our endeavour to accelerate global drug discovery and development practice.”